What to do about AI in health?
Although artificial intelligence in health has shown great promise, pressure is mounting for regulators around the world to act, as AI tools demonstrate potentially harmful outcomes.
Although artificial intelligence in health has shown great promise, pressure is mounting for regulators around the world to act, as AI tools demonstrate potentially harmful outcomes.
By
The MIT Sloan School of Management announced that Daniel Tarullo will serve as a distinguished fellow at MIT’s Golub Center for Finance and Policy (GCFP).
Vaccines are an especially risky proposition for pharmaceutical manufacturers since the costs are higher than for other types of drugs and demand could drop drastically once a crisis is over.
Cell and gene therapies represent an exciting and complex new treatment type, with the potential to treat a vast range of indications.
HSI Professor Joseph Doyle is interviewed on Freakomomics, M.D. podcast
By
Long touted by economists, carbon taxes are transparent, enforceable, and adjustable. An MIT Sloan finance professor explains her support.
By
We are excited to announce the appointment of Dr. Ben S. Bernanke as our Distinguished Senior Fellow for the 2020-2021 academic year [...]
By
“Climate risk is investment risk.” BlackRock CEO Larry Fink shares his thoughts on how to create a net zero carbon world by 2050.
By
How Much Do Guarantees and Bailouts Cost the Government? Deborah Lucas NO. 3–2024 MAY 2024 FEDERAL RESERVE BANK OF ATLANTA’S POLICY HUB
By
The Golub Center for Finance and Policy (GCFP) at the MIT Sloan School of Management is pleased to announce the appointment of Chester Spatt as a Distinguished Senior Fellow to lead the Center’s research on regulation of financial markets and institutions. In addition to playing a substantial role i...